PVLA · Palvella Therapeutics

The thesis

Palvella Therapeutics has a modestly better-than-even chance of beating the S&P 500 over the next three months while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision. The review timeline is intact, cash was $236.7 million at 30 September 2026, and the cutaneous venous malformations Phase 3 is still guided to start before year end. Review news and that trial start decide the shares until the decision, which lands just after the three-month window.

The shares fell for three straight sessions after the 9 November 2026 high. They closed at $153.18 on 12 November 2026, down from $163.94 on 11 November 2026 and the $175.92 record close of 6 November 2026 (adjusted daily closes). No company release or filing explains the drop. At the Stifel 2026 Healthcare Conference on 10 November 2026, management repeated the 28 February 2027 action date and a cutaneous venous malformations Phase 3 start before the end of 2026, according to the StockAnalysis summary of the transcript.

At $153.18, the shares sit well below the $213.85 consensus target MarketBeat listed on 9 November 2026, after the third-quarter report. The market is pricing a likely approval while still discounting the launch analysts model. An FDA delay, a complete response letter or a slip in the trial start would show the view is wrong.

Bullish and bearish views on Palvella Therapeutics, Inc.

The bull case on Palvella Therapeutics, Inc. (PVLA), in brief: the review timeline is unchanged. The bear case: approval is still binary.

Bull case

• The review timeline is unchanged. The 5 November 2026 8-K exhibit restates Priority Review and a 28 February 2027 Prescription Drug User Fee Act (PDUFA) target action date for microcystic lymphatic malformations. It also restates a planned US launch in the first half of 2027, if approved.
• Targets sit far above the price. Canaccord Genuity raised its target to $243 from $232 on 9 November 2026 and kept Buy; Oppenheimer raised to $232 from $210 on 6 November 2026. Raymond James ($230, from $226) and Craig-Hallum ($230, from $205) also raised targets after the 5 November 2026 report, per the StockAnalysis news feed.
• Cash covers the launch build. Cash, cash equivalents and short-term investments were $236.7 million at 30 September 2026 (8-K exhibit). On the 5 November 2026 call, management said cash funds operations "deep into the commercial launch," including a standalone US launch and the cutaneous venous malformations Phase 3.
• Pivotal results are strong. Palvella reported on 31 August 2026 that 86% of SELVA Phase 3 participants who completed the efficacy evaluation were rated much or very much improved at Week 24. All six efficacy endpoints reached p<0.001 (company-reported).
• Systemic exposure is low. Palvella said on 12 October 2026 that a Phase 3 substudy showed QTORIN rapamycin blood exposure at least 40-fold lower than published oral sirolimus data. That supports a topical safety profile in label discussions.
• The pipeline is due to widen this quarter. Management reiterated on 10 November 2026 at Stifel that the cutaneous venous malformations Phase 3 starts before the end of 2026. A Phase 2 start for QTORIN pitavastatin is guided for the same quarter (5 November 2026 call).

Bear case

• Approval is still binary. The FDA has accepted the file and has not approved it. The company's 5 November 2026 risk language cites "limited experience in commercial manufacturing."
• Losses are widening into launch. The third-quarter net loss was $24.6 million, or $1.70 per share, against $11.3 million a year earlier (8-K exhibit, 5 November 2026). The company has no product revenue.
• The shares gave back gains without news. The close fell from $175.92 on 6 November 2026 to $153.18 on 12 November 2026, below the $156.85 close of 5 November 2026, the day of the report (adjusted daily closes). The post-report gain is gone.
• Insiders sold through the autumn. SEC Form 4 filings show director George M. Jenkins sold 27,500 shares at an average $151.53 on 11 September to 15 September 2026 and 27,500 more at an average $130.16 on 12 October to 14 October 2026, under a Rule 10b5-1 plan. Chief Operating Officer Kathleen Goin sold 4,313 shares at an average $124.58 on 21 October 2026 under the same type of plan.
• The quarterly loss read was mixed. Benzinga called the $1.70 loss per share a beat of a $(1.82) consensus on 5 November 2026, while the Associated Press said it fell short of a $1.65 Zacks average.

Price setup

The last close was $153.18 on 12 November 2026, 14.9% below the 52-week intraday high of $179.95 set on 9 November 2026. The record close is $175.92 on 6 November 2026. The shares are down 1.9% over three months, against a $156.13 close on 14 August 2026 (adjusted daily closes).

As of 12 November 2026, the 50-day moving average is $143.62 and the 200-day moving average is $130.09. Both sit below the price and both are rising. The 50-day average is the next reference below the price. A close under it would mean the shares had given back most of the move that followed the FDA's 28 October 2026 filing acceptance.

The 52-week closing low is $76.43 on 5 February 2026. That is the level the shares held before the SELVA Phase 3 results and the filing. No earnings report falls inside the next 30 days.

Catalysts ahead

• 8 December 2026: CEO Wes Kaupinen speaks at Ligand Pharmaceuticals' Investor Day. The next scheduled venue for FDA review and launch-readiness commentary before year end.
• 21 December 2026: James R. Treat, M.D. becomes Chief Medical Officer. Puts a new medical leader in the role during the final stretch of the FDA review.
• ~31 December 2026 (est.): Phase 3 start in cutaneous venous malformations and Phase 2 start for QTORIN pitavastatin (company guidance: fourth quarter 2026). Shows whether the pipeline widens on schedule; a slip into 2027 narrows the case to the lead indication.
• 28 February 2027: FDA PDUFA target action date for QTORIN rapamycin in microcystic lymphatic malformations. Decides approval; it falls just after the three-month window, so the shares trade on review news until then.

What would change the view

A daily close below $127, under the 200-day moving average and the 15 October 2026 close of $127.34, which would erase the move that followed the FDA's filing acceptance. An FDA delay to the 28 February 2027 action date or a complete response letter would also break the case.

The risks this note tracks, each with what would confirm it:

• The review is delayed or ends in a complete response letter, for example over label wording, manufacturing or inspection findings. Confirmed by: a Palvella disclosure of an FDA information request, inspection finding or extended action date before 28 February 2027.
• The pullback from the 6 November 2026 record close extends with no company news as holders take gains ahead of the decision. Confirmed by: a daily close under the 50-day moving average, $143.62 as of 12 November 2026, without a company disclosure.
• Pre-launch spending outruns management's runway statement as hiring ramps into the decision. Confirmed by: a financing announced ahead of launch, or a fourth-quarter cash decline well above the third-quarter pace at the next results report.
• The fourth-quarter trial starts slip, narrowing the case to the lead indication. Confirmed by: no announced first-patient dosing in the cutaneous venous malformations Phase 3 or the pitavastatin Phase 2 by 31 December 2026.
• Continued insider selling signals limited conviction from those closest to the company. Confirmed by: new SEC Form 4 filings showing large director or officer sales outside Rule 10b5-1 plans.

What it trades with

Palvella trades mainly on its own regulatory calendar. Rare-disease and small-cap biotech sentiment moves it at the margin. The large moves have followed company disclosures: the 28 October 2026 filing acceptance and the 5 November 2026 report. Analyst target changes clustered around those dates. The 11 November to 12 November 2026 decline came with no company news, which points to profit-taking or sector flows. Ligand Pharmaceuticals is linked through the Investor Day on 8 December 2026, where Palvella's CEO is scheduled to speak.